Biohaven Pharmaceutical Holding Ltd. Statistics
Share Statistics
Biohaven Pharmaceutical Holding Ltd. has 101.12M shares outstanding. The number of shares has increased by 17.83% in one year.
| Shares Outstanding | 101.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 7.08% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 88.62M |
| Failed to Deliver (FTD) Shares | 88 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 9.15M, so 9.07% of the outstanding shares have been sold short.
| Short Interest | 9.15M |
| Short % of Shares Out | 9.07% |
| Short % of Float | 10.35% |
| Short Ratio (days to cover) | 9.45 |
Valuation Ratios
The PE ratio is -7.47 and the forward PE ratio is -7.97.
| PE Ratio | -7.47 |
| Forward PE | -7.97 |
| PS Ratio | 0 |
| Forward PS | 167.1 |
| PB Ratio | 7.12 |
| P/FCF Ratio | -9.1 |
| PEG Ratio | n/a |
Enterprise Valuation
Biohaven Pharmaceutical Holding Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 7.98, with a Debt / Equity ratio of 0.
| Current Ratio | 7.98 |
| Quick Ratio | 7.99 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.95% and return on capital (ROIC) is -94.71%.
| Return on Equity (ROE) | -0.95% |
| Return on Assets (ROA) | -0.8% |
| Return on Capital (ROIC) | -94.71% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.71M |
| Employee Count | 239 |
| Asset Turnover | 0 |
| Inventory Turnover | -8.51 |
Taxes
| Income Tax | -1.38M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -1.36% in the last 52 weeks. The beta is 4.12, so Biohaven Pharmaceutical Holding Ltd.'s price volatility has been higher than the market average.
| Beta | 4.12 |
| 52-Week Price Change | -1.36% |
| 50-Day Moving Average | 48.89 |
| 200-Day Moving Average | 43.52 |
| Relative Strength Index (RSI) | 33.49 |
| Average Volume (20 Days) | 1.03M |
Income Statement
In the last 12 months, Biohaven Pharmaceutical Holding Ltd. had revenue of $0 and earned -$408.17M in profits. Earnings per share was $-5.73.
| Revenue | 0 |
| Gross Profit | -3.37M |
| Operating Income | -436.05M |
| Net Income | -408.17M |
| EBITDA | -429.14M |
| EBIT | - |
| Earnings Per Share (EPS) | -5.73 |
Balance Sheet
The company has $248.40M in cash and $30.88M in debt, giving a net cash position of $217.53M.
| Cash & Cash Equivalents | 248.40M |
| Total Debt | 30.88M |
| Net Cash | 217.53M |
| Retained Earnings | -499.29M |
| Total Assets | 510.52M |
| Working Capital | 288.21M |
Cash Flow
In the last 12 months, operating cash flow was -$331.73M and capital expenditures -$3.05M, giving a free cash flow of -$334.77M.
| Operating Cash Flow | -331.73M |
| Capital Expenditures | -3.05M |
| Free Cash Flow | -334.77M |
| FCF Per Share | -4.7 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BHVN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -14.89% |
| FCF Yield | -8.61% |
Analyst Forecast
The average price target for BHVN is $60.5, which is 57.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $60.5 |
| Price Target Difference | 57.3% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 4.55 |
| Piotroski F-Score | 2 |